ShanXi C&Y Pharmaceutical Group Co.,LTD. 300254.SZ Stock
ShanXi C&Y Pharmaceutical Group Co.,LTD. Price Chart
ShanXi C&Y Pharmaceutical Group Co.,LTD. 300254.SZ Financial and Trading Overview
Contents
- ShanXi C&Y Pharmaceutical Group Co.,LTD. Price Chart
- ShanXi C&Y Pharmaceutical Group Co.,LTD. 300254.SZ Financial and Trading Overview
- Valuation Measures
- Trading Information
- Financial Highlights
- Profile of ShanXi C&Y Pharmaceutical Group Co.,LTD.
- Q&A For ShanXi C&Y Pharmaceutical Group Co.,LTD. Stock
| ShanXi C&Y Pharmaceutical Group Co.,LTD. stock price | 9.33 CNY |
| Previous Close | 9.18 CNY |
| Open | 9.16 CNY |
| Bid | 8.77 CNY x 0 |
| Ask | 8.79 CNY x 0 |
| Day's Range | 8.77 - 9.19 CNY |
| 52 Week Range | 4.98 - 11.13 CNY |
| Volume | 9.9M CNY |
| Avg. Volume | 8.67M CNY |
| Market Cap | 2.12B CNY |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 87.700005 |
| EPS (TTM) | 0.1 CNY |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | July 11, 2019 |
| 1y Target Est | N/A |
300254.SZ Valuation Measures
| Enterprise Value | 2.66B CNY |
| Trailing P/E | 87.700005 |
| Forward P/E | 16.865387 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.6510513 |
| Price/Book (mrq) | 3.5348651 |
| Enterprise Value/Revenue | 3.328 |
| Enterprise Value/EBITDA | 30.878 |
Trading Information
ShanXi C&Y Pharmaceutical Group Co.,LTD. Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 11.13 CNY |
| 52 Week Low | 4.98 CNY |
| 50-Day Moving Average | 8.29 CNY |
| 200-Day Moving Average | 8.49 CNY |
300254.SZ Share Statistics
| Avg. Volume (3 month) | 8.67M CNY |
| Avg. Daily Volume (10-Days) | 17M CNY |
| Shares Outstanding | 241.62M |
| Float | 194.47M |
| Short Ratio | N/A |
| % Held by Insiders | 26.90% |
| % Held by Institutions | 4.64% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | 40.00% |
| Payout Ratio | 0 |
| Last Split Factor | 12:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2023 |
| Most Recent Quarter (mrq) | December 31, 2023 |
| Next Fiscal Year End | December 31, 2024 |
Profitability
| Profit Margin | 3.15% |
| Operating Margin (ttm) | 6.59% |
| Gross Margin | 67.78% |
| EBITDA Margin | 10.77% |
Management Effectiveness
| Return on Assets (ttm) | 1.38% |
| Return on Equity (ttm) | 6.46% |
Income Statement
| Revenue (ttm) | 799.31M CNY |
| Revenue Per Share (ttm) | 3.31 CNY |
| Quarterly Revenue Growth (yoy) | 16.50% |
| Gross Profit (ttm) | N/A |
| EBITDA | 86.15M CNY |
| Net Income Avi to Common (ttm) | 25.2M CNY |
| Diluted EPS (ttm) | 0.1 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 132M CNY |
| Total Cash Per Share (mrq) | 0.55 CNY |
| Total Debt (mrq) | 393.81M CNY |
| Total Debt/Equity (mrq) | 50.59 CNY |
| Current Ratio (mrq) | 0.963 |
| Book Value Per Share (mrq) | 2.481 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 37.81M CNY |
| Levered Free Cash Flow (ttm) | -302959296 CNY |
Profile of ShanXi C&Y Pharmaceutical Group Co.,LTD.
| Country | China |
| State | N/A |
| City | Datong |
| Address | No. 1378, Heng'an Street |
| ZIP | 037010 |
| Phone | 86 35 2611 6426 |
| Website | https://www.cy-pharm.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
ShanXi C&Y Pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of medicine and health food products. It offers anti-infective drugs, anti-allergic drugs, respiratory system drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, antidepressants, medicines, pharmaceutical raw materials, and intermediates, etc. The company's product portfolio includes Fosfomycin tromethamine powder, Mezlocillin sodium sulbactam sodium for injection, Ebastine tablets, Tamsulosin hydrochloride sustained release capsules, Cinacalcet hydrochloride tablets, Apixaban tablets, Rivaroxaban tablets, Flouxetine hydrochloride capsules, Ambroxol hydrochloride dispersible tablets, Smectite powder, Vitamin AD drops, and Baoling Yunbao oral liquid, as well as provides DNA gene preservation services. It also provides medical and health services and commercial services, such as medical diagnosis, gene preservation, and pregnancy environment testing services. The company was formerly known as Shanxi C&Y Pharmaceutical Co., Ltd. and changed its name to Shanxi C&Y Pharmaceutical Group Co., Ltd. in September 2014. Shanxi C&Y Pharmaceutical Group Co., LTD. was founded in 2005 and is headquartered in Datong, China.
Q&A For ShanXi C&Y Pharmaceutical Group Co.,LTD. Stock
What is a current 300254.SZ stock price?
ShanXi C&Y Pharmaceutical Group Co.,LTD. 300254.SZ stock price today per share is 9.33 CNY.
How to purchase ShanXi C&Y Pharmaceutical Group Co.,LTD. stock?
You can buy 300254.SZ shares on the Shenzhen exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ShanXi C&Y Pharmaceutical Group Co.,LTD.?
The stock symbol or ticker of ShanXi C&Y Pharmaceutical Group Co.,LTD. is 300254.SZ.
Which industry does the ShanXi C&Y Pharmaceutical Group Co.,LTD. company belong to?
The ShanXi C&Y Pharmaceutical Group Co.,LTD. industry is Drug Manufacturers-Specialty & Generic.
How many shares does ShanXi C&Y Pharmaceutical Group Co.,LTD. have in circulation?
The max supply of ShanXi C&Y Pharmaceutical Group Co.,LTD. shares is 241.62M.
What is ShanXi C&Y Pharmaceutical Group Co.,LTD. Price to Earnings Ratio (PE Ratio)?
ShanXi C&Y Pharmaceutical Group Co.,LTD. PE Ratio is 93.29999500 now.
What was ShanXi C&Y Pharmaceutical Group Co.,LTD. earnings per share over the trailing 12 months (TTM)?
ShanXi C&Y Pharmaceutical Group Co.,LTD. EPS is 0.1 CNY over the trailing 12 months.
Which sector does the ShanXi C&Y Pharmaceutical Group Co.,LTD. company belong to?
The ShanXi C&Y Pharmaceutical Group Co.,LTD. sector is Healthcare.